Scleroderma Therapeutics Market Size, Share & Trends Analysis Report By Type (Localized Scleroderma, Systemic Sclerosis, Diffuse Sclerosis, Others), By Drug Class (Immunosuppressors, Phosphodiesterase 5 inhibitors – PHA, Endothelin Receptor Antagonists, Prostacyclin Analogs, Others), By Route of Administration (Parenteral, Oral, Topical), By End-User (Hospitals, Clinics, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Scleroderma Therapeutics Market Size

The global scleroderma therapeutics market size was valued at USD 2.77 billion in 2025 and is projected to grow from USD 2.88 billion in 2026 to USD 3.95 billion by 2034, registering a CAGR of 4.03% during the forecast period from 2026 to 2034. North America dominated the scleroderma therapeutics market with a market share of 39.2% in 2025.

Scleroderma therapeutics refer to medical treatments and therapies aimed at managing scleroderma, a chronic autoimmune disease that causes the skin and connective tissues to harden and tighten. The condition can affect internal organs as well, leading to complications in the heart, lungs, kidneys, and digestive system. Therapeutics for scleroderma include medications to control inflammation, suppress the immune system, and manage symptoms such as skin thickening, pain, and blood vessel problems.

The market is experiencing significant growth, driven by advancements in immunotherapies, anti-fibrotic treatments, and a deeper understanding of autoimmune diseases. As the global prevalence of scleroderma rises, particularly among women and adults, there is an increasing demand for effective treatments to manage complex symptoms such as fibrosis and lung involvement. The development of targeted therapies, including CAR T-cell therapies and biologics, is revolutionizing the management of systemic sclerosis and localized scleroderma.

• A notable example is the collaboration between the Scleroderma Research Foundation (SRF) and Sanofi, announced in April 2023, where Sanofi contributed its first experimental agent to CONQUEST, a clinical trial platform designed to expedite the development of promising treatments for scleroderma. This collaboration aims to identify which agents should advance from Phase 2b to Phase 3 trials, showcasing the critical role of partnerships in accelerating the search for effective therapies.

With growing awareness of scleroderma and its complications, coupled with expanding research and development in immunotherapy, the market is poised for continued growth. This expansion is further supported by regulatory approvals, government initiatives, and the increasing adoption of personalized treatment approaches, offering hope for improved patient outcomes.

Segmentation Analysis

By Type

Systemic sclerosis is the largest segment in the global market, accounting for the highest revenue. This is due to its severe impact on multiple organ systems, including the lungs, heart, and kidneys, which often results in life-threatening complications. The complexity and multi-organ involvement increase the demand for specialized treatments, driving the market for effective therapies to manage these extensive challenges associated with systemic sclerosis.

Request Customizationto receive a tailored report.

By Drug Class

Immunosuppressors dominate the market for scleroderma therapeutics due to their ability to suppress the overactive immune system, thereby reducing inflammation and slowing disease progression. These drugs are essential in treating both localized and systemic sclerosis. By helping to control the immune response and prevent fibrosis, immunosuppressors are critical in managing scleroderma symptoms and minimizing complications, which makes them a cornerstone of treatment regimens for affected patients.

By Route of Administration

The oral route of administration holds the largest market share in the global market, primarily due to its ease of use and convenience for patients. Oral medications, such as immunosuppressors and endothelin receptor antagonists, are widely prescribed for managing systemic sclerosis and its complications. The non-invasive nature of oral treatments enhances patient adherence, offering a more accessible and patient-friendly approach to long-term disease management.

By End-User

Hospitals are the leading end-users in the global market, driving the highest market revenue. This is because hospitals are equipped with specialized medical teams and advanced diagnostic tools necessary for treating complex cases of systemic sclerosis, particularly those involving multi-organ complications. The infrastructure in hospitals supports the administration of complex therapies and provides comprehensive care for patients, making them the preferred healthcare setting for scleroderma treatment.

Speak to an Analystto discuss market opportunities.

Regional Insights

North America: Dominant Region with 39.8% Market Share

North America holds a dominant position in the global scleroderma therapeutics market, driven by a high rate of early diagnosis and increasing awareness of the disease. The region benefits from the presence of leading pharmaceutical companies, advanced research institutions, and a robust healthcare system. The widespread adoption of innovative therapies, including immunosuppressants and targeted biologics, is further accelerating market growth. Moreover, North America’s strong focus on clinical trials and cutting-edge treatment innovations solidifies its leadership, driving sustained demand for effective scleroderma therapies.

Unlock Regional Insightsto access country-level data, & regional trends.

Asia Pacific: Fastest Growing Region with the Highest Market Cagr

Asia-Pacific is poised to register the fastest growth in the global scleroderma therapeutics market, with the highest projected CAGR. This growth is driven by increased awareness of autoimmune diseases, improved healthcare access, and rising demand for advanced treatment options in countries like Japan, China, and India. Government initiatives and expanding healthcare infrastructure are also contributing to the rapid adoption of novel therapies. As the region continues to invest in research and development, it is expected to play a pivotal role in shaping the future of scleroderma treatment, further fueling market expansion.

Countries Insights

• U.S.- The U.S. leads the scleroderma therapeutics market, benefiting from significant investments in research and development, along with strong regulatory support for clinical trials. In October 2023, Kyverna Therapeutics received FDA clearance for its third IND application for KYV-101, a CAR T-cell therapy targeting diffuse cutaneous systemic sclerosis. This approval paved the way for Phase 1/2 trials, underscoring the U.S.'s role in advancing innovative treatments for scleroderma.
• Germany- Germany is a key player in Europe’s scleroderma therapeutics market, driven by advanced treatment options and an increasing number of clinical trials. For example, Kyverna Therapeutics launched Phase 1/2 trials of KYV-101 in Germany in addition to the U.S., targeting diffuse cutaneous systemic sclerosis and lupus nephritis. Germany’s focus on clinical research and adoption of novel therapies enhances its position as a leader in scleroderma therapeutics in Europe.
• Canada- In Canada, the market growth is driven by rising investments in research and developments for scleroderma in the country. For instance, in 2022, BLR Bio received a USD 780,000 grant in collaboration with experts at the University of Saskatchewan, Canada, from the Canadian Institutes of Health Research to advance the study of BLR-200 in scleroderma. The ongoing research has shown promising in vivo results, highlighting the potential of BLR-200 as a therapeutic option for scleroderma.
• India– India’s scleroderma therapeutics market is experiencing rapid growth, driven by rising awareness of autoimmune diseases, expanding healthcare infrastructure, and increased access to advanced treatment options. Collaborations between local healthcare providers and international pharmaceutical companies are introducing innovative therapies, improving disease management, and enhancing patient outcomes. These factors are contributing to better diagnosis, improved treatments, and a growing focus on scleroderma care in India.
• Japan- Japan is experiencing significant growth in its market, driven by heightened awareness of autoimmune diseases and strong government support for healthcare innovation. The country’s robust research and development activities, particularly in immunotherapy and anti-fibrotic treatments, are introducing novel treatment options for scleroderma patients. Japan’s rapid adoption of new therapies and focus on clinical advancements contribute to its expanding role.

Company Market Share

Key players in the global scleroderma therapeutics industry are increasingly focusing on adopting a range of key business strategies to strengthen their position and drive growth. These strategies include strategic collaborations with academic institutions, healthcare providers, and other pharmaceutical companies to pool resources, knowledge, and expertise.

Amylyx Pharmaceuticals: An Emerging Player in the Global Scleroderma Therapeutics Market

AMYLYX Pharmaceuticals is dedicated to advancing therapies for rare diseases, with a particular focus on scleroderma. The company is committed to developing novel treatments that address the underlying mechanisms of fibrosis and inflammation, which are central to the progression of scleroderma. By targeting these key pathways, AMYLYX aims to offer potential breakthroughs that could significantly improve patient outcomes, especially for those experiencing severe complications related to the disease.

Recent developments by AMYLYX Pharmaceuticals:

• In January 2025, Amylyx Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) lifted the clinical hold on the Phase 1 trial of AMX0114, an investigational antisense oligonucleotide targeting calpain-2 for amyotrophic lateral sclerosis (ALS). This development marks a significant step forward, with Amylyx planning to open U.S. trial sites for screening, enrollment, and dosing.

List of Key and Emerging Players in Scleroderma Therapeutics Market